Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands.
Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Nat Rev Cancer. 2018 Jul;18(7):407-418. doi: 10.1038/s41568-018-0007-6.
The recent advances in in vitro 3D culture technologies, such as organoids, have opened new avenues for the development of novel, more physiological human cancer models. Such preclinical models are essential for more efficient translation of basic cancer research into novel treatment regimens for patients with cancer. Wild-type organoids can be grown from embryonic and adult stem cells and display self-organizing capacities, phenocopying essential aspects of the organs they are derived from. Genetic modification of organoids allows disease modelling in a setting that approaches the physiological environment. Additionally, organoids can be grown with high efficiency from patient-derived healthy and tumour tissues, potentially enabling patient-specific drug testing and the development of individualized treatment regimens. In this Review, we evaluate tumour organoid protocols and how they can be utilized as an alternative model for cancer research.
近年来,体外 3D 培养技术(如类器官)的发展为开发新型、更接近生理的人类癌症模型开辟了新途径。这些临床前模型对于将基础癌症研究更有效地转化为癌症患者的新型治疗方案至关重要。野生型类器官可从胚胎和成体干细胞中生长,并表现出自组织能力,模拟其来源器官的重要方面。类器官的遗传修饰允许在接近生理环境的条件下进行疾病建模。此外,类器官可以从患者来源的健康和肿瘤组织中高效生长,这可能使患者特异性药物测试和个体化治疗方案的开发成为可能。在这篇综述中,我们评估了肿瘤类器官的方案,以及它们如何作为癌症研究的替代模型被利用。